Table 1.
Demographic data of the raloxifene group versus the placebo group
| Risperidone + Raloxifene group (N = 25) | Risperidone + Placebo group (N = 25) | p-value | ||
|---|---|---|---|---|
| Age (±SD) |
61.96 ± 4.49 |
60.44 ± 5.28 |
p > 0.05 |
|
| Education |
Illiterate |
4 (36.36%) |
7 (63.64%) |
p > 0.05 |
| School |
17 (51.52%) |
16 (48.48%) |
||
| University |
3 (50%) |
3 (50%) |
||
| Positive family history |
13 (42%) |
15 (60%) |
p > 0.05 |
|
| Age of onset |
34.96 ± 11.69 |
29.40 ± 8.57 |
p > 0.05 |
|
| Duration |
17.24 ± 12.03 |
13.64 ± 12.41 |
p > 0.05 |
|
| Previous treatment |
Risperidone |
7 (41.12%) |
10 (58.88%) |
p > 0.05 |
| Other atypical |
3 (75.0%) |
1 (25.0%) |
||
| Typical |
11 (50.0%) |
11 (50.0%) |
||
| |
Combination |
4 (57.14%) |
3 (42.86%) |
|
| IQ |
Normal |
24 (52.17%) |
22 (47.83%) |
p > 0.05 |
| Borderline | 1 (25.0%) | 3 (75.0%) | ||